User contributions for Edzelco
Jump to navigation
Jump to search
8 May 2024
- 01:5801:58, 8 May 2024 diff hist +22 User:Edzelco →Pages Authored/Co-authored/Collaborated current
- 01:5501:55, 8 May 2024 diff hist +45,965 Toripalimab-tpzi No edit summary current
- 01:5301:53, 8 May 2024 diff hist 0 N File:LOQTORZI Dosage.png No edit summary current
20 April 2024
- 03:2103:21, 20 April 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 03:2003:20, 20 April 2024 diff hist +38,269 Cipaglucosidase alfa-atga No edit summary current
18 April 2024
- 12:4812:48, 18 April 2024 diff hist +96 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 12:4512:45, 18 April 2024 diff hist −220 Momelotinib No edit summary current
- 12:4412:44, 18 April 2024 diff hist +34,290 Momelotinib No edit summary
- 12:1212:12, 18 April 2024 diff hist +26,053 Motixafortide No edit summary current
- 11:4911:49, 18 April 2024 diff hist +2,390 Pozelimab-bbfg No edit summary current
- 11:4211:42, 18 April 2024 diff hist +39,181 Palovarotene No edit summary current
- 11:1611:16, 18 April 2024 diff hist +32,847 Elranatamab-bcmm No edit summary current
17 April 2024
- 08:0808:08, 17 April 2024 diff hist +53 N Elranatamab-bcmm Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0808:08, 17 April 2024 diff hist +53 N Palovarotene Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0808:08, 17 April 2024 diff hist +53 N Pozelimab-bbfg Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0708:07, 17 April 2024 diff hist +53 N Motixafortide Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0708:07, 17 April 2024 diff hist +53 N Momelotinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0608:06, 17 April 2024 diff hist +53 N Cipaglucosidase alfa-atga Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0508:05, 17 April 2024 diff hist +53 N Etrasimod Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0508:05, 17 April 2024 diff hist +53 N Zilucoplan Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0408:04, 17 April 2024 diff hist +53 N Bimekizumab Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0408:04, 17 April 2024 diff hist +53 N Vamorolone Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0408:04, 17 April 2024 diff hist +53 N Mirikizumab-mrkz Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}" current
- 08:0308:03, 17 April 2024 diff hist +53 N Toripalimab-tpzi Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}"
- 08:0208:02, 17 April 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 08:0208:02, 17 April 2024 diff hist +25,648 N Fruquintinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F..." current
- 07:5307:53, 17 April 2024 diff hist +26 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:5307:53, 17 April 2024 diff hist 0 Taurolidine, heparin No edit summary current
- 07:5207:52, 17 April 2024 diff hist +9,993 N Taurolidine, heparin Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients..."
- 07:4407:44, 17 April 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:4407:44, 17 April 2024 diff hist +36 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:4307:43, 17 April 2024 diff hist +19 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:4307:43, 17 April 2024 diff hist +32,783 N Repotrectinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru..." current
- 07:3407:34, 17 April 2024 diff hist 0 Efbemalenograstim alfa-vuxw No edit summary current
- 07:3307:33, 17 April 2024 diff hist +51 Efbemalenograstim alfa-vuxw No edit summary
- 07:3207:32, 17 April 2024 diff hist +20,075 N Efbemalenograstim alfa-vuxw Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle...."
16 April 2024
- 05:5005:50, 16 April 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 05:5005:50, 16 April 2024 diff hist +34,175 N Capivasertib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based..." current
- 05:2805:28, 16 April 2024 diff hist +15 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 05:2705:27, 16 April 2024 diff hist +33,311 N Iptacopan Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me..." current
15 April 2024
- 07:2507:25, 15 April 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 07:2407:24, 15 April 2024 diff hist +17,228 N Vutrisiran Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj..." current
24 March 2024
18 February 2024
- 03:1503:15, 18 February 2024 diff hist −58 User:Edzelco No edit summary
16 February 2024
- 19:0419:04, 16 February 2024 diff hist +297 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 19:0319:03, 16 February 2024 diff hist −303 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
- 19:0219:02, 16 February 2024 diff hist +292 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 19:0219:02, 16 February 2024 diff hist −180 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
11 February 2024
- 22:2422:24, 11 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 22:2322:23, 11 February 2024 diff hist +1,081 N Mavacamten Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART..." current
- 00:4200:42, 11 February 2024 diff hist −258 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
- 00:4000:40, 11 February 2024 diff hist +396 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 00:3900:39, 11 February 2024 diff hist −207 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
10 February 2024
- 19:0519:05, 10 February 2024 diff hist +19 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 19:0519:05, 10 February 2024 diff hist +23 Oteseconazole No edit summary current
- 19:0419:04, 10 February 2024 diff hist +25,740 N Oteseconazole Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co..."
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label3.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label2.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA structure.png No edit summary current
- 18:4718:47, 10 February 2024 diff hist −18 User:Edzelco →Edzel Lorraine Co, DMD, MD
7 February 2024
- 00:4700:47, 7 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:4700:47, 7 February 2024 diff hist +44 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:4700:47, 7 February 2024 diff hist +25,546 N Lutetium (177Lu) vipivotide tetraxetan Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout..." current
- 00:4400:44, 7 February 2024 diff hist 0 N File:Pluvicto label.png No edit summary current
- 00:4400:44, 7 February 2024 diff hist 0 N File:Pluvicto structure.png No edit summary current
6 February 2024
- 00:5700:57, 6 February 2024 diff hist +35 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:5700:57, 6 February 2024 diff hist +33,106 N Nivolumab and relatlimab-rmbw Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im..." current
- 00:5600:56, 6 February 2024 diff hist 0 N File:Nivolumab and relatlimab-rmbw label.png No edit summary current
- 00:2600:26, 6 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:2300:23, 6 February 2024 diff hist −2 Ganaxolone No edit summary current
- 00:2300:23, 6 February 2024 diff hist +24,999 Ganaxolone No edit summary
- 00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle carton.png No edit summary current
- 00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle suspension label 50mg.png No edit summary current
- 00:2100:21, 6 February 2024 diff hist 0 N File:Ganaloxone structure.png No edit summary current
2 February 2024
- 15:4915:49, 2 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4915:49, 2 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4815:48, 2 February 2024 diff hist −2 Pacritinib No edit summary current
- 15:4715:47, 2 February 2024 diff hist +29,299 N Pacritinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi..."
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Bottle Label.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Carton Label.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib supply.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib structure.png No edit summary current
1 February 2024
- 16:5316:53, 1 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5316:53, 1 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5216:52, 1 February 2024 diff hist +15 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5216:52, 1 February 2024 diff hist +22,285 Mitapivat No edit summary current
- 16:2316:23, 1 February 2024 diff hist −23,245 Mitapivat Blanked the page Tag: Blanking
- 16:2216:22, 1 February 2024 diff hist +1,030 Mitapivat Undo revision 1736932 by Edzelco (talk) Tag: Undo
- 16:2216:22, 1 February 2024 diff hist −1,030 Mitapivat No edit summary
- 16:2116:21, 1 February 2024 diff hist −16 Mitapivat No edit summary
- 16:2016:20, 1 February 2024 diff hist −36 Mitapivat No edit summary
- 16:1916:19, 1 February 2024 diff hist +461 Mitapivat Undo revision 1736928 by Edzelco (talk) Tag: Undo
- 16:1916:19, 1 February 2024 diff hist −461 Mitapivat No edit summary
- 16:1616:16, 1 February 2024 diff hist −4 Mitapivat No edit summary Tag: Manual revert
- 16:1616:16, 1 February 2024 diff hist +4 Mitapivat No edit summary
- 16:1416:14, 1 February 2024 diff hist −2 Mitapivat No edit summary Tag: Manual revert
- 16:1416:14, 1 February 2024 diff hist +2 Mitapivat No edit summary
- 16:1316:13, 1 February 2024 diff hist +23,297 N Mitapivat Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mitapivat |aOrAn=a |drugClass=pyruvate kinase activator |indicationType=treatment |indication=hemolytic anemia in adults with pyruvate kinase (PK) deficiency |adverseReactions=estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia |fdaLIADAdult=PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew,..."
- 16:0816:08, 1 February 2024 diff hist 0 N File:Mitapivat 5mg.png No edit summary current
- 16:0816:08, 1 February 2024 diff hist 0 N File:Mitapivat 5mg tablet blister pack.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 20mg.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 20mg tablet blister pack.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 50mg.png No edit summary current
- 16:0716:07, 1 February 2024 diff hist 0 N File:Mitapivat 50mg tablet blister pack.png No edit summary current
- 16:0616:06, 1 February 2024 diff hist 0 N File:Mitapivat structure.png No edit summary current
- 16:0616:06, 1 February 2024 diff hist 0 N File:Mitapivat supply.png No edit summary current
- 15:4615:46, 1 February 2024 diff hist +21 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4615:46, 1 February 2024 diff hist +26,967 N Sutimlimab-jome Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Sutimlimab-jome |aOrAn=a |drugClass=classical complement inhibitor |indicationType=treatment |indication=hemolysis in adults with cold agglutinin disease (CAD) |adverseReactions=in the CADENZA study (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud's phenomenon. The most common adverse reactions in the CARDINAL study (incidence ≥..." current
- 15:4415:44, 1 February 2024 diff hist 0 N File:Sutimlimab-jome packaging.png No edit summary current
- 15:3215:32, 1 February 2024 diff hist +20 User:Edzelco No edit summary
- 15:3115:31, 1 February 2024 diff hist +24,023 N Faricimab-svoa Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Faricimab-svoa |aOrAn=a |drugClass=vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor |indicationType=treatment |indication=patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) |adverseReactions=cataract (15%) and [[conjunctival hemorrhage]..." current
- 15:0515:05, 1 February 2024 diff hist +32 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0515:05, 1 February 2024 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0415:04, 1 February 2024 diff hist +25 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0415:04, 1 February 2024 diff hist +17 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0315:03, 1 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0315:03, 1 February 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0215:02, 1 February 2024 diff hist +31 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0215:02, 1 February 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0115:01, 1 February 2024 diff hist +18 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0015:00, 1 February 2024 diff hist +17 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:0015:00, 1 February 2024 diff hist +22 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 14:5914:59, 1 February 2024 diff hist +18,438 N Tebentafusp-tebn Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Tebentafusp-tebn |aOrAn=a |drugClass=bispecific gp100 peptide-HLA-directed CD3 T cell engager |indicationType=treatment |indication=HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting. The most..." current
- 01:4901:49, 1 February 2024 diff hist +604 Abrocitinib No edit summary current
- 01:4601:46, 1 February 2024 diff hist +13,636 Abrocitinib No edit summary
- 01:4601:46, 1 February 2024 diff hist 0 N File:Abrocitinib 200mg.png No edit summary current
- 01:4601:46, 1 February 2024 diff hist 0 N File:Abrocitinib 100mg.png No edit summary current
- 01:4301:43, 1 February 2024 diff hist 0 N File:Abrocitinib 50mg.png No edit summary current
- 01:3901:39, 1 February 2024 diff hist 0 N File:Abrocitinib supply.png No edit summary current
- 01:3201:32, 1 February 2024 diff hist 0 N File:Abrocitinib.png No edit summary current
- 01:3101:31, 1 February 2024 diff hist +22,842 N Abrocitinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |indicationType=treatment |indication=adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOS..."
- 01:0601:06, 1 February 2024 diff hist −279 Daridorexant No edit summary current
31 January 2024
- 21:1721:17, 31 January 2024 diff hist +31,199 N Daridorexant Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=daridorexant |aOrAn=an |drugClass=orexin receptor antagonist |indicationType=treatment |indication=adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |adverseReactions=Common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) include headache and somnolence or fatigue..."
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 3.png No edit summary current
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 2.png No edit summary current
- 21:1521:15, 31 January 2024 diff hist 0 N File:Clinical Studies 1.png No edit summary current
- 21:0721:07, 31 January 2024 diff hist 0 N File:Effects of hepatic impairment and renal impairment on daridorexant PK.png No edit summary current
- 21:0721:07, 31 January 2024 diff hist 0 N File:Effect of daridorexant on the PK of other compounds.png No edit summary current
- 21:0621:06, 31 January 2024 diff hist 0 N File:Effect of co-administered compounds on the PK of daridorexant.png No edit summary current
- 21:0121:01, 31 January 2024 diff hist 0 N File:Packaging 3.png No edit summary current
- 21:0121:01, 31 January 2024 diff hist 0 N File:Packaging 2.png No edit summary current
- 21:0021:00, 31 January 2024 diff hist 0 N File:Packaging 1.png No edit summary current
- 20:4920:49, 31 January 2024 diff hist 0 N File:Daridorexant.png No edit summary current
25 January 2024
- 00:2500:25, 25 January 2024 diff hist +5,566 N Orbifloxacin Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Orbifloxacin |aOrAn=a |drugClass=fluoroquinolone carboxylic acid derivatives |indicationType=treatment |indication=urinary tract infections (cystitis) in dogs caused by susceptible strains of <i>Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli</i> and <i>Enterococcus faecalis</i>. |adverseReactions=In a field study, when the tablet formulation of orbifloxacin..." current
- 00:1600:16, 25 January 2024 diff hist 0 N File:Orbifloxacin packaging.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin suspension 2.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin suspension.png No edit summary current
- 00:1500:15, 25 January 2024 diff hist 0 N File:Orbifloxacin structure.png No edit summary current
23 January 2024
- 14:2814:28, 23 January 2024 diff hist +30,972 N Ado-Trastuzumab Emtansine Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Ado-trastuzumab emtansine |aOrAn=a |drugClass=HER2-targeted antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=1.) patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: a.) Received prior therapy for metastatic disease, or b.) Developed disease recurrence during or wi..." current
- 14:2414:24, 23 January 2024 diff hist 0 N File:Ado-trastuzumab emtansine packaging 160mg.png No edit summary current
- 14:2214:22, 23 January 2024 diff hist 0 N File:Ado-trastuzumab emtansine packaging.png No edit summary current
- 14:1914:19, 23 January 2024 diff hist 0 N File:Ado-trastuzumab emtansine supply.png No edit summary current
- 14:1914:19, 23 January 2024 diff hist 0 N File:Ado-trastuzumab emtansine structure.png No edit summary current
22 January 2024
- 23:3223:32, 22 January 2024 diff hist +17,319 N Omacetaxine mepesuccinate Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Omacetaxine mepesuccinate (SYNRIBO) |aOrAn=an |drugClass=injection |indicationType=treatment |indication=adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) |fdaLIADAdult=*Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for 14 consecutive days of a 28-day cycle. *Maint..." current
- 23:0823:08, 22 January 2024 diff hist +1,322 N Adipiodone Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Adipiodone meglumine |aOrAn=a |drugClass=a tri-iodinated benzoate derivative and an ionic dimeric contrast agent |indicationType=procedure |indication=diagnostic imaging, as this agent blocks x-ray and appears opaque on x-ray film; thereby it enhances the visibility of the bile ducts and gallbladder during cholangiography and cholecystography procedures |adverseReactions=epilepsy, abdominal pain, and tremor..." current
- 21:1721:17, 22 January 2024 diff hist 0 N File:Adipiodine FDA-Approved Drugs.png No edit summary current
- 21:1221:12, 22 January 2024 diff hist 0 N File:Structure of Adipiodine.png No edit summary current
- 16:4316:43, 22 January 2024 diff hist +1,686 Oclacitinib No edit summary current
- 16:4216:42, 22 January 2024 diff hist 0 N File:Oclatinib.png No edit summary current
- 16:3716:37, 22 January 2024 diff hist +3,415 N Oclacitinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |aOrAn=an |drugClass=immunomodulator |indicationType=treatment |indication=pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age |blackBoxWarningBody=This product is not for human use. Keep this and all drugs out of reach of children. For use in dogs only. Wash hands immediately after handling the tablets. In case of accidental eye contact, flush immediately with..."
- 16:3416:34, 22 January 2024 diff hist 0 N File:APOQUEL tablets 16 mg Tablet Bottle Label.png No edit summary current
- 16:3416:34, 22 January 2024 diff hist 0 N File:APOQUEL tablets 5.4 mg Tablet Bottle Label.png No edit summary current
- 16:3416:34, 22 January 2024 diff hist 0 N File:APOQUEL tablets 3.6 mg Tablet Bottle Label.png No edit summary current
- 15:4915:49, 22 January 2024 diff hist +331 N Absorbable gelatin sponge Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Gelatin Sponge, Absorbable |aOrAn=a |drugClass=sterile, gelatin-base surgical sponge |indicationType=treatment |indication=bleeding as an adjunct to hemostasis when conventional procedure is ineffective. |brandNames=*Gelfoam |lookAlike=*Gelaspon *SurgiFoam }}" current
- 15:2515:25, 22 January 2024 diff hist +1 AbobotulinumtoxinA No edit summary current
- 15:2415:24, 22 January 2024 diff hist +2 AbobotulinumtoxinA No edit summary
- 15:2415:24, 22 January 2024 diff hist 0 AbobotulinumtoxinA No edit summary
- 15:2215:22, 22 January 2024 diff hist −4 AbobotulinumtoxinA No edit summary
- 15:2015:20, 22 January 2024 diff hist −6 Allergy medical therapy →Contraindicated Medications current
- 15:2015:20, 22 January 2024 diff hist +111 Allergy medical therapy No edit summary
- 02:3002:30, 22 January 2024 diff hist +21 AbobotulinumtoxinA No edit summary
- 01:3701:37, 22 January 2024 diff hist +167 AbobotulinumtoxinA Undo revision 1736837 by Edzelco (talk) Tag: Undo
- 01:3701:37, 22 January 2024 diff hist −167 AbobotulinumtoxinA No edit summary
- 01:3301:33, 22 January 2024 diff hist −6 AbobotulinumtoxinA No edit summary Tag: Manual revert
- 01:3201:32, 22 January 2024 diff hist +6 AbobotulinumtoxinA No edit summary
- 01:3201:32, 22 January 2024 diff hist +9 AbobotulinumtoxinA No edit summary
- 01:3001:30, 22 January 2024 diff hist +7 AbobotulinumtoxinA No edit summary
- 01:2701:27, 22 January 2024 diff hist −28 AbobotulinumtoxinA No edit summary
- 01:2501:25, 22 January 2024 diff hist 0 AbobotulinumtoxinA No edit summary
- 01:2501:25, 22 January 2024 diff hist 0 AbobotulinumtoxinA No edit summary
- 01:2301:23, 22 January 2024 diff hist −6 AbobotulinumtoxinA No edit summary
- 01:2201:22, 22 January 2024 diff hist +77 AbobotulinumtoxinA No edit summary
- 01:1501:15, 22 January 2024 diff hist −22 AbobotulinumtoxinA No edit summary
- 01:1001:10, 22 January 2024 diff hist +92 2-(4-chlorphenoxy)-ethanol No edit summary current
- 01:0701:07, 22 January 2024 diff hist +183 2-(4-chlorphenoxy)-ethanol No edit summary
- 01:0401:04, 22 January 2024 diff hist −1 2-(4-chlorphenoxy)-ethanol No edit summary
- 01:0301:03, 22 January 2024 diff hist +24 2-(4-chlorphenoxy)-ethanol No edit summary
- 00:5900:59, 22 January 2024 diff hist −50 2-(4-chlorphenoxy)-ethanol No edit summary
- 00:5800:58, 22 January 2024 diff hist −126 2-(4-chlorphenoxy)-ethanol No edit summary
- 00:4400:44, 22 January 2024 diff hist +413 2-(4-chlorphenoxy)-ethanol No edit summary
- 00:2600:26, 22 January 2024 diff hist +1,249 2-(4-chlorphenoxy)-ethanol No edit summary
- 00:2100:21, 22 January 2024 diff hist +112 2-(4-chlorphenoxy)-ethanol No edit summary
- 00:2100:21, 22 January 2024 diff hist 0 N File:2-(4-CHLOROPHENOXY)ETHANOL.png No edit summary current
- 00:1300:13, 22 January 2024 diff hist −4 AbobotulinumtoxinA No edit summary
- 00:1200:12, 22 January 2024 diff hist −130 AbobotulinumtoxinA No edit summary
- 00:1000:10, 22 January 2024 diff hist −4 AbobotulinumtoxinA No edit summary
- 00:0900:09, 22 January 2024 diff hist +138 AbobotulinumtoxinA Undo revision 1736812 by Edzelco (talk) Tag: Undo
- 00:0700:07, 22 January 2024 diff hist −138 AbobotulinumtoxinA No edit summary
- 00:0100:01, 22 January 2024 diff hist +25 AbobotulinumtoxinA No edit summary
21 January 2024
- 23:5823:58, 21 January 2024 diff hist −5 AbobotulinumtoxinA No edit summary
- 23:5123:51, 21 January 2024 diff hist +29,225 AbobotulinumtoxinA No edit summary
- 22:1822:18, 21 January 2024 diff hist +3 AbobotulinumtoxinA No edit summary
- 22:1622:16, 21 January 2024 diff hist +821 N AbobotulinumtoxinA Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Dysport |indication=Dysport is FDA approved for the treatment of cervical dystonia in adults, improvement of moderate to severe frown lines on the glabellar zone (eyebrows) of adults aged 65 years old or younger for a short period of time, and spasticity in people aged 2 years or older. |adverseReactions=Common adverse reactions include difficulty in breathing, speak..."
- 21:3021:30, 21 January 2024 diff hist +53 2-(4-chlorphenoxy)-ethanol No edit summary
- 21:2921:29, 21 January 2024 diff hist −42 2-(4-chlorphenoxy)-ethanol Blanked the page Tag: Blanking
- 21:2921:29, 21 January 2024 diff hist −20 2-(4-chlorphenoxy)-ethanol No edit summary
- 21:2821:28, 21 January 2024 diff hist +62 N 2-(4-chlorphenoxy)-ethanol Created page with "{{DrugProjectFormSinglePage |authorTag={{CMG}}; {{EdzelCo}} }}"
- 01:0701:07, 21 January 2024 diff hist +13,116 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu... current
- 00:4300:43, 21 January 2024 diff hist +4,518 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 00:3400:34, 21 January 2024 diff hist +104 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
- 00:3400:34, 21 January 2024 diff hist −102 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias Tag: Visual edit
- 00:3200:32, 21 January 2024 diff hist +9 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
- 00:3200:32, 21 January 2024 diff hist −6 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
- 00:3100:31, 21 January 2024 diff hist 0 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
- 00:3000:30, 21 January 2024 diff hist +156 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
- 00:2900:29, 21 January 2024 diff hist +7 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias
- 00:2800:28, 21 January 2024 diff hist −39 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for the Management of Patients With HCM and Ventricular Arrhythmias Tag: Visual edit
- 00:2700:27, 21 January 2024 diff hist +10,642 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 00:0100:01, 21 January 2024 diff hist +4,658 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
20 January 2024
- 23:4923:49, 20 January 2024 diff hist +7 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for Pharmacologic Management of Patients With Obstructive HCM
- 23:4823:48, 20 January 2024 diff hist +68 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for Pharmacologic Management of Patients With Obstructive HCM
- 23:4723:47, 20 January 2024 diff hist +18 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for Pharmacologic Management of Patients With Obstructive HCM Tag: Visual edit
- 23:4623:46, 20 January 2024 diff hist −58 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for Pharmacologic Management of Patients With Obstructive HCM
- 23:4523:45, 20 January 2024 diff hist +7,479 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 02:0702:07, 20 January 2024 diff hist +1 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for ICD Placement in High-Risk Patients With HCM
- 02:0702:07, 20 January 2024 diff hist −7 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for ICD Placement in High-Risk Patients With HCM
- 02:0602:06, 20 January 2024 diff hist +5,825 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
4 January 2024
- 16:1016:10, 4 January 2024 diff hist +2,631 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 15:3215:32, 4 January 2024 diff hist +1 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendations for Individuals Who Are Genotype-Positive, Phenotype-Negative
- 15:3115:31, 4 January 2024 diff hist +1,701 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
21 December 2023
- 16:2916:29, 21 December 2023 diff hist +1,155 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Genetics and Family Testing
- 16:2516:25, 21 December 2023 diff hist 0 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Genetics and Family Testing
- 16:2516:25, 21 December 2023 diff hist +970 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Genetics and Family Testing
7 December 2023
- 22:0922:09, 7 December 2023 diff hist +5,071 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 21:5721:57, 7 December 2023 diff hist −33 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Exercise Stress Testing
- 17:0617:06, 7 December 2023 diff hist +1,576 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Exercise Stress Testing
- 16:3316:33, 7 December 2023 diff hist +1,598 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 16:2816:28, 7 December 2023 diff hist +3 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Heart Rhythm Assessment
- 16:2816:28, 7 December 2023 diff hist +1,653 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 15:3015:30, 7 December 2023 diff hist −4 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Heart Rhythm Assessment
- 15:2915:29, 7 December 2023 diff hist +4 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Heart Rhythm Assessment
- 15:2915:29, 7 December 2023 diff hist +3,560 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 15:2215:22, 7 December 2023 diff hist +3,792 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 15:1415:14, 7 December 2023 diff hist +1 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:1415:14, 7 December 2023 diff hist −1 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:1315:13, 7 December 2023 diff hist −546 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography Tag: Visual edit
- 15:1215:12, 7 December 2023 diff hist −14 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:1115:11, 7 December 2023 diff hist −6 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:1115:11, 7 December 2023 diff hist −141 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0915:09, 7 December 2023 diff hist −1 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0915:09, 7 December 2023 diff hist +581 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0815:08, 7 December 2023 diff hist −3 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0715:07, 7 December 2023 diff hist −4 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0515:05, 7 December 2023 diff hist +14 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0415:04, 7 December 2023 diff hist +3 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0315:03, 7 December 2023 diff hist +3 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 15:0215:02, 7 December 2023 diff hist +5,159 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 14:5214:52, 7 December 2023 diff hist +52 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography
- 14:5114:51, 7 December 2023 diff hist +27 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Echocardiography Tag: Visual edit
- 14:5014:50, 7 December 2023 diff hist +1,168 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 14:4614:46, 7 December 2023 diff hist +647 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 14:4314:43, 7 December 2023 diff hist −1 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Multidisciplinary HCM Centers
- 14:4314:43, 7 December 2023 diff hist −3 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →Recommendation for Multidisciplinary HCM Centers
- 14:4214:42, 7 December 2023 diff hist +1,181 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
14 November 2023
- 03:3503:35, 14 November 2023 diff hist +846 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volu...
- 03:2903:29, 14 November 2023 diff hist +660 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
- 02:0702:07, 14 November 2023 diff hist 0 Cardiomyopathy 2023 ESC Guideline Recommendations →Recommendations for the Management of Patients with Restrictive Cardiomyopathy current
- 02:0702:07, 14 November 2023 diff hist +15,502 Cardiomyopathy 2023 ESC Guideline Recommendations /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
13 November 2023
- 07:4307:43, 13 November 2023 diff hist −37 Eczema differential diagnosis No edit summary current
- 07:4307:43, 13 November 2023 diff hist −37 Eczema causes No edit summary current
- 07:4307:43, 13 November 2023 diff hist −37 Eczema pathophysiology No edit summary current
- 07:4307:43, 13 November 2023 diff hist −37 Eczema classification No edit summary current
- 07:4207:42, 13 November 2023 diff hist −37 Eczema historical perspective No edit summary current
- 07:4207:42, 13 November 2023 diff hist −37 Eczema overview No edit summary current
- 07:4207:42, 13 November 2023 diff hist −39 Eczema (patient information) No edit summary current
- 07:4107:41, 13 November 2023 diff hist −37 Eczema No edit summary current
- 07:4007:40, 13 November 2023 diff hist +7 Template:EdzelCo No edit summary current
- 07:2607:26, 13 November 2023 diff hist −41 Cardiomyopathy 2023 ESC Guideline Recommendations No edit summary
- 07:2607:26, 13 November 2023 diff hist −41 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy No edit summary
- 07:1707:17, 13 November 2023 diff hist +47 Cardiomyopathy differential diagnosis No edit summary current
- 07:1707:17, 13 November 2023 diff hist −72 Cardiomyopathy differential diagnosis No edit summary
- 07:1407:14, 13 November 2023 diff hist +18 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy →2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
- 07:1307:13, 13 November 2023 diff hist +2 Cardiomyopathy 2023 ESC Guideline Recommendations /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 07:1307:13, 13 November 2023 diff hist +1 Cardiomyopathy 2023 ESC Guideline Recommendations /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 07:1307:13, 13 November 2023 diff hist −3 Cardiomyopathy 2023 ESC Guideline Recommendations /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 07:1307:13, 13 November 2023 diff hist +500 Cardiomyopathy 2023 ESC Guideline Recommendations Undo revision 1736591 by Edzelco (talk) Tag: Undo
- 07:1207:12, 13 November 2023 diff hist −500 Cardiomyopathy 2023 ESC Guideline Recommendations /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 07:1207:12, 13 November 2023 diff hist +7 Cardiomyopathy 2023 ESC Guideline Recommendations No edit summary
- 07:0407:04, 13 November 2023 diff hist −1 Cardiomyopathy 2023 ESC Guideline Recommendations No edit summary Tag: Manual revert
- 07:0407:04, 13 November 2023 diff hist −1 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy No edit summary
- 07:0407:04, 13 November 2023 diff hist +240 Cardiomyopathy →Guidelines current
- 07:0107:01, 13 November 2023 diff hist +104 Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy No edit summary
- 07:0107:01, 13 November 2023 diff hist +1 Cardiomyopathy 2023 ESC Guideline Recommendations No edit summary
- 07:0007:00, 13 November 2023 diff hist +99 N Cardiomyopathy 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy Created page with "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy"
- 06:5906:59, 13 November 2023 diff hist +62 Cardiomyopathy 2023 ESC Guideline Recommendations No edit summary
- 06:5806:58, 13 November 2023 diff hist +25,629 N Cardiomyopathy 2023 ESC Guideline Recommendations Created page with "=== <b><font color="red"> 2023 ESC Guideline Recommendations </font> </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/el..."
- 06:5806:58, 13 November 2023 diff hist −25,631 Cardiomyopathy Guidelines /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=376226... current Tag: Replaced
- 06:5706:57, 13 November 2023 diff hist +342 Template:Cardiomyopathy No edit summary current
- 06:5106:51, 13 November 2023 diff hist 0 Template:Cardiomyopathy No edit summary Tag: Manual revert
- 06:5006:50, 13 November 2023 diff hist 0 Template:Cardiomyopathy No edit summary
- 06:4906:49, 13 November 2023 diff hist +70 Cardiomyopathy →Guidelines
- 06:4806:48, 13 November 2023 diff hist −5 Cardiomyopathy →Guidelines
- 06:4706:47, 13 November 2023 diff hist +14 Cardiomyopathy Guidelines No edit summary
- 06:4706:47, 13 November 2023 diff hist +100 Cardiomyopathy Guidelines No edit summary
- 06:4606:46, 13 November 2023 diff hist +26,414 N Cardiomyopathy Guidelines Created page with "=== <b><font color="red"> 2023 ESC Guideline Recommendations </font> </b> <ref name="pmid37622657">{{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/el..."
- 06:4506:45, 13 November 2023 diff hist −26,415 Cardiomyopathy →Guidelines Tag: Replaced
- 06:4506:45, 13 November 2023 diff hist −8 Template:Cardiomyopathy No edit summary Tag: Manual revert
- 06:4406:44, 13 November 2023 diff hist +8 Template:Cardiomyopathy No edit summary
- 06:4306:43, 13 November 2023 diff hist 0 Template:Cardiomyopathy No edit summary
- 06:4206:42, 13 November 2023 diff hist +1 Template:Cardiomyopathy No edit summary
- 06:4206:42, 13 November 2023 diff hist −28 Template:Cardiomyopathy No edit summary
- 06:4106:41, 13 November 2023 diff hist +5 Template:Cardiomyopathy No edit summary
- 06:3806:38, 13 November 2023 diff hist +97 Template:Cardiomyopathy No edit summary
12 November 2023
- 07:5207:52, 12 November 2023 diff hist +1,700 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=376226...
- 07:4507:45, 12 November 2023 diff hist +1 Cardiomyopathy →Recommendations for Septal Reduction Therapy
- 07:4407:44, 12 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Septal Reduction Therapy
- 07:4407:44, 12 November 2023 diff hist +1,235 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=376226...
11 November 2023
- 14:4414:44, 11 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Family Screening and Follow-up Evaluation of Relatives
- 14:4414:44, 11 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Psychological Support in Patients and Family Members with Cardiomyopathies
- 14:4214:42, 11 November 2023 diff hist +2,218 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=376226...
- 14:3514:35, 11 November 2023 diff hist +2,494 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=376226...
- 04:5204:52, 11 November 2023 diff hist +2 Cardiomyopathy No edit summary
- 04:5204:52, 11 November 2023 diff hist 0 Cardiomyopathy No edit summary
- 04:5104:51, 11 November 2023 diff hist +14 Cardiomyopathy No edit summary
- 04:5004:50, 11 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:4604:46, 11 November 2023 diff hist −4 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:4504:45, 11 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:4404:44, 11 November 2023 diff hist +516 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:4104:41, 11 November 2023 diff hist +966 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:1304:13, 11 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy Tag: Visual edit
- 04:1204:12, 11 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:1204:12, 11 November 2023 diff hist −4 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:1104:11, 11 November 2023 diff hist −231 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:1104:11, 11 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:1004:10, 11 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 04:0804:08, 11 November 2023 diff hist +1,359 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
10 November 2023
- 13:2713:27, 10 November 2023 diff hist +5 Cardiomyopathy →Guidelines
- 13:2613:26, 10 November 2023 diff hist +5 Cardiomyopathy →Guidelines
- 13:2613:26, 10 November 2023 diff hist +1 Cardiomyopathy →Guidelines
- 13:2513:25, 10 November 2023 diff hist −6 Cardiomyopathy →Guidelines
- 13:2513:25, 10 November 2023 diff hist +26 Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volume= 142 | issue=...
- 13:2413:24, 10 November 2023 diff hist −4 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=376226...
- 13:2413:24, 10 November 2023 diff hist +28 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 13:2213:22, 10 November 2023 diff hist +4 Cardiomyopathy →Guidelines
- 13:2213:22, 10 November 2023 diff hist +5 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 13:1813:18, 10 November 2023 diff hist +5 Cardiomyopathy →Guidelines
- 13:1713:17, 10 November 2023 diff hist +2 Cardiomyopathy /* 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volume= 142 | issue=...
- 13:1713:17, 10 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 13:1713:17, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Management of Atrial Fibrillation and Atrial Flutter in Patients with Cardiomyopathy
- 13:1713:17, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Cardiac Implantation in Patients with Cardiomyopathy
- 13:1713:17, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Computed Tomography and Nuclear Imaging
- 13:1713:17, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies
- 13:1613:16, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies
- 13:1613:16, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies
- 13:1613:16, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies
- 13:1613:16, 10 November 2023 diff hist −5 Cardiomyopathy No edit summary
- 13:1513:15, 10 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Diagnostic Work-up in Cardiomyopathies
- 13:1513:15, 10 November 2023 diff hist −5 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 13:1413:14, 10 November 2023 diff hist +19 Cardiomyopathy No edit summary
- 13:1313:13, 10 November 2023 diff hist −5 Cardiomyopathy /* 20232020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy {{cite journal| author=Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P | display-authors=etal| title=2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2020 | volume= 142 | issu...
- 13:1313:13, 10 November 2023 diff hist +764 Cardiomyopathy No edit summary
- 10:4710:47, 10 November 2023 diff hist +471 Cardiomyopathy →Recommendations for Implantable Cardioverter Defibrillator in Patients with Cardiomyopathy
- 09:0109:01, 10 November 2023 diff hist +1,441 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 08:4908:49, 10 November 2023 diff hist −18 Cardiomyopathy →textcolor="Blue" Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:4808:48, 10 November 2023 diff hist +17 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:4708:47, 10 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Cardiac Implantation in Patients with Cardiomyopathy.
- 08:4608:46, 10 November 2023 diff hist +2,834 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 08:3808:38, 10 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.
- 08:3808:38, 10 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Diagnostic Work-up in Cardiomyopathies.
- 08:3708:37, 10 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:3708:37, 10 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
- 08:3708:37, 10 November 2023 diff hist +1,173 Cardiomyopathy /* 2023 ESC Guideline Recommendations {{cite journal| author=Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C | display-authors=etal| title=2023 ESC Guidelines for the management of cardiomyopathies. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 37 | pages= 3503-3626 | pmid=37622657 | doi=10.1093/eurheartj/ehad194 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622657...
- 02:2102:21, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:2002:20, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:2002:20, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:2002:20, 10 November 2023 diff hist −148 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1802:18, 10 November 2023 diff hist 0 User:Edzelco →Oral Presentation
- 02:1802:18, 10 November 2023 diff hist 0 User:Edzelco →Poster Presentation
- 02:1802:18, 10 November 2023 diff hist 0 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
- 02:1802:18, 10 November 2023 diff hist 0 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 02:1602:16, 10 November 2023 diff hist +1 User:Edzelco →Pages Authored/Co-authored/Collaborated Tag: Manual revert
- 02:1602:16, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated Tag: Manual revert
- 02:1602:16, 10 November 2023 diff hist +2 User:Edzelco →Pages Authored/Co-authored/Collaborated Tag: Manual revert
- 02:1602:16, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated Tag: Manual revert
- 02:1502:15, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated Tag: Manual revert
- 02:1502:15, 10 November 2023 diff hist +1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1502:15, 10 November 2023 diff hist +1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1502:15, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1502:15, 10 November 2023 diff hist −4 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1502:15, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1402:14, 10 November 2023 diff hist +3 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1402:14, 10 November 2023 diff hist +1 User:Edzelco →Pages Authored/Co-authored/Collaborated Tag: Manual revert
- 02:1402:14, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1402:14, 10 November 2023 diff hist −9 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1402:14, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1302:13, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1302:13, 10 November 2023 diff hist +5 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1302:13, 10 November 2023 diff hist +5 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1302:13, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1202:12, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1202:12, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1202:12, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1202:12, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1202:12, 10 November 2023 diff hist −26 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1102:11, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1002:10, 10 November 2023 diff hist +13 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:1002:10, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:0902:09, 10 November 2023 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:0902:09, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:0902:09, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:0802:08, 10 November 2023 diff hist +1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:0802:08, 10 November 2023 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:0802:08, 10 November 2023 diff hist −1 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 02:0702:07, 10 November 2023 diff hist +59 User:Edzelco →Pages Authored/Co-authored/Collaborated
9 November 2023
- 11:1611:16, 9 November 2023 diff hist +20 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 11:1411:14, 9 November 2023 diff hist −1 Cardiomyopathy No edit summary
- 11:1411:14, 9 November 2023 diff hist −82 Cardiomyopathy No edit summary
- 11:1311:13, 9 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 11:0711:07, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 11:0711:07, 9 November 2023 diff hist +189 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 11:0611:06, 9 November 2023 diff hist +27 Cardiomyopathy →Recommendations for Computed Tomography and Nuclear Imaging
- 11:0611:06, 9 November 2023 diff hist +27 Cardiomyopathy →Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
- 11:0611:06, 9 November 2023 diff hist +27 Cardiomyopathy →Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.
- 11:0611:06, 9 November 2023 diff hist +54 Cardiomyopathy →Recommendations for Diagnostic Work-up in Cardiomyopathies.
- 11:0611:06, 9 November 2023 diff hist +54 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 11:0511:05, 9 November 2023 diff hist +28 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 11:0511:05, 9 November 2023 diff hist +231 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 11:0411:04, 9 November 2023 diff hist +231 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 11:0411:04, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 11:0211:02, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 10:5010:50, 9 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 10:4910:49, 9 November 2023 diff hist +5 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:3009:30, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2909:29, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2909:29, 9 November 2023 diff hist +1,218 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2509:25, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2309:23, 9 November 2023 diff hist +6 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2209:22, 9 November 2023 diff hist +3 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies. Tag: Manual revert
- 09:2209:22, 9 November 2023 diff hist −5 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2209:22, 9 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2209:22, 9 November 2023 diff hist +6 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2109:21, 9 November 2023 diff hist +3 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2109:21, 9 November 2023 diff hist −8 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2109:21, 9 November 2023 diff hist −4 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:2009:20, 9 November 2023 diff hist +191 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:1909:19, 9 November 2023 diff hist +445 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:1809:18, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:1709:17, 9 November 2023 diff hist +354 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:1609:16, 9 November 2023 diff hist +167 Cardiomyopathy →Recommendations for Computed Tomography and Nuclear Imaging
- 09:1609:16, 9 November 2023 diff hist +107 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 09:1509:15, 9 November 2023 diff hist +334 Cardiomyopathy →Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
- 09:1409:14, 9 November 2023 diff hist +298 Cardiomyopathy →Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.
- 09:1109:11, 9 November 2023 diff hist +1 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:1109:11, 9 November 2023 diff hist +61 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:1009:10, 9 November 2023 diff hist −1 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:1009:10, 9 November 2023 diff hist +50 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies. Tag: Visual edit
- 09:0909:09, 9 November 2023 diff hist +8 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies. Tag: Visual edit
- 09:0809:08, 9 November 2023 diff hist −456 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:0709:07, 9 November 2023 diff hist +570 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:0609:06, 9 November 2023 diff hist −153 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:0509:05, 9 November 2023 diff hist +1 Cardiomyopathy →Recommendations for Genetic Counselling and Testing in Cardiomyopathies.
- 09:0409:04, 9 November 2023 diff hist +23 Cardiomyopathy →Recommendations for Computed Tomography and Nuclear Imaging
- 09:0309:03, 9 November 2023 diff hist −54 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 09:0309:03, 9 November 2023 diff hist −54 Cardiomyopathy →Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
- 09:0309:03, 9 November 2023 diff hist +59 Cardiomyopathy →Recommendations for Computed Tomography and Nuclear Imaging
- 09:0209:02, 9 November 2023 diff hist +114 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 09:0209:02, 9 November 2023 diff hist +114 Cardiomyopathy →Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
- 09:0209:02, 9 November 2023 diff hist +23 Cardiomyopathy →Recommendations for Echocardiographic Evaluation in Patients with Cardiomyopathies.
- 09:0109:01, 9 November 2023 diff hist +2 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 09:0009:00, 9 November 2023 diff hist −4 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies. Tag: Manual revert
- 09:0009:00, 9 November 2023 diff hist +4 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 09:0009:00, 9 November 2023 diff hist +3 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 09:0009:00, 9 November 2023 diff hist −4 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:5908:59, 9 November 2023 diff hist −2 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies. Tag: Manual revert
- 08:5908:59, 9 November 2023 diff hist +1 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:5908:59, 9 November 2023 diff hist +1 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:5908:59, 9 November 2023 diff hist +4 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:5908:59, 9 November 2023 diff hist −5 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies. Tag: Manual revert
- 08:5808:58, 9 November 2023 diff hist 0 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:5808:58, 9 November 2023 diff hist +5 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:5808:58, 9 November 2023 diff hist +18 Cardiomyopathy →Recommendations for Cardiac Magnetic Resonance Indication in Patients with Cardiomyopathies.
- 08:5708:57, 9 November 2023 diff hist +23 Cardiomyopathy →Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.
- 08:5708:57, 9 November 2023 diff hist +61 Cardiomyopathy →Recommendations for Laboratory Tests in the Diagnosis of Cardiomyopathies.
- 08:5608:56, 9 November 2023 diff hist +9 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams. Tag: Manual revert
- 08:5508:55, 9 November 2023 diff hist −6 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5508:55, 9 November 2023 diff hist −5 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5508:55, 9 November 2023 diff hist +2 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5408:54, 9 November 2023 diff hist −63 Cardiomyopathy →Recommendations for Diagnostic Work-up in Cardiomyopathies.
- 08:5308:53, 9 November 2023 diff hist +114 Cardiomyopathy →Recommendations for Diagnostic Work-up in Cardiomyopathies.
- 08:5208:52, 9 November 2023 diff hist +21 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5208:52, 9 November 2023 diff hist +5 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5208:52, 9 November 2023 diff hist −1 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5108:51, 9 November 2023 diff hist +17 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5008:50, 9 November 2023 diff hist +62 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:5008:50, 9 November 2023 diff hist −1 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:4908:49, 9 November 2023 diff hist +6 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams. Tag: Visual edit
- 08:4908:49, 9 November 2023 diff hist −39 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams. Tag: Manual revert
- 08:4908:49, 9 November 2023 diff hist +39 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.
- 08:4808:48, 9 November 2023 diff hist +2 Cardiomyopathy →Recommendations for the Provision of Service of Multidisciplinary Cardiomyopathy Teams.